Virological phenotype switches under salvage therapy with lopinavir–ritonavir in heavily pretreated HIV-1 vertically infected children
- 1 January 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (2) , 247-255
- https://doi.org/10.1097/00002030-200401230-00014
Abstract
To investigate the effects of salvage therapy with lopinavir-ritonavir on HIV-1 phenotype in heavily antiretroviral experienced HIV-infected children. Twenty antiretroviral experienced HIV-infected children were studied during a mean of time of 16.1 months from initiation of the treatment with lopinavir-ritonavir. Besides CD4 T cells, viral load and clinical status, we analyzed 91 serial viral isolates to study the phenotype, and biological clones derived from co-cultivation techniques. We observed an increase in CD4 T cells, a statistically significant decrease in viral load and clinical benefits from 3 months after treatment. Ninety per cent of children had SI/X4 bulk isolates in peripheral blood mononuclear cells at study entry. The viral phenotype changed to non syncitium-inducing (NSI)/R5 in 94% of the children after a mean of 5.7 months (95% confidence interval, 2.1-9.3 months) of salvage therapy. The remaining 10% of children had NSI/R5 isolates at entry and at all follow-up study. Similar results were found at the clonal level. Thus, at study entry in PBMC of three children with bulk syncitium-inducing (SI) phenotype, we recovered 65 biologic clones, 56 being SI and nine NSI. After salvage therapy bulk isolates changed to NSI and of 40 biologic clones recovered only five were SI and the rest were NSI. Our data suggest that lopinavir-ritonavir salvage therapy led not only to a viral load decrease but also to a phenotypic change. X4 virus appeared to be preferentially suppressed. Shifts in co-receptor usage may thereby contribute to the clinical efficacy of anti-HIV drugs in vertically infected infants.Keywords
This publication has 36 references indexed in Scilit:
- Lopinavir/RitonavirDrugs, 2003
- Characterizing Immune Reconstitution after Long-Term Highly Active Antiretroviral Therapy in Pediatric AIDSAIDS Research and Human Retroviruses, 2002
- Impact of Cytokines on Replication in the Thymus of Primary Human Immunodeficiency Virus Type 1 Isolates from InfantsJournal of Virology, 2002
- Impact of antiretroviral protocols on dynamics of AIDS progression markersArchives of Disease in Childhood, 2002
- Viral phenotype affects the thymic production of new T cells in HIV-1-infected childrenAIDS, 2001
- Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The NetherlandsThe Journal of Pediatrics, 2000
- Conversion Rate towards a Syncytium‐Inducing (SI) Phenotype during Different Stages of Human Immunodeficiency Virus Type 1 Infection and Prognostic Value of SI Phenotype for Survival after AIDS DiagnosisThe Journal of Infectious Diseases, 1999
- Dynamics of Syncytium-Inducing and Non-Syncytium-Inducing Type 1 Human Immunodeficiency Viruses during Primary InfectionAIDS Research and Human Retroviruses, 1997
- Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.Journal of Clinical Investigation, 1997
- CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1Science, 1996